PharmEasy Unlisted Share Description –
PharmEasy-parent API Holdings is India’s largest digital healthcare platform which operates an integrated, end-to-end business that aims to provide solutions for the healthcare needs of consumers across the following critical stages-
A. providing digital tools and information on illness and wellness
B. offering teleconsultation
C. offering diagnostics and radiology tests
D. delivering treatment protocols including products and devices
API Holdings has developed a custom-built technology platform designed to deliver benefits across the healthcare value chain through an interconnected network. The company collaborates closely with various stakeholders, including consumers, pharmaceutical companies, wholesalers, pharmacies, hospitals, doctors, clinics, and diagnostic labs. Its expanding presence across India, combined with a connected ecosystem approach and diverse synergistic offerings, has allowed API Holdings to foster strong relationships throughout the healthcare value chain, encompassing wholesalers, chemists, consultants, consumers, and other enterprises.
What is PharmEasy?
PharmEasy is a comprehensive consumer healthcare “super app” that offers users on-demand, home-delivered access to a diverse array of prescription medications, over-the-counter (OTC) pharmaceuticals, and other healthcare products. In addition to these offerings, PharmEasy provides extensive diagnostic testing services and teleconsultations, effectively addressing various healthcare needs for its consumers.
Read Also: Sterlite Power Unlisted Shares
Products & Services of the PharmEasy
- Prescription Medications
- Over-the-counter (OTC) Products
- Diagnostic Services
- Teleconsultations
- Health Packages
- Home Delivery
- User-Friendly Mobile App
PharmEasy Subsidiaries Companies
- API Holdings Limited (Holding Company)
- Threpsi Solutions Private Ltd.
- AKP Healthcare Private Ltd.
- Eastern Agencies Healthcare Private Ltd.
- Venkatesh Medico Private Ltd.
- Aushad Pharma Distributors Private Limited
- Avighna Medicare Private Limited
- Aycon Graph Connect Private Limited
- Aryan Wellness Private Limited
- Ayro Retail Solutions Private Ltd.
- D.C Agencies Private Limited
- Mahaveer MediSales Private Limited
- Docon Technologies Private Ltd.
- Ascent Wellness and Pharma Solutions Private Ltd.
- Reenav Pharma Private Limited
- AHWSPL India Private Limited
- Thyrocare Technologies Limited
- Akna Medical Private Limited
Key Highlights –
- The company is expanding its product business in Semi Urban + Rural markets across India.
- PharmEasy’s revenue from operations declined by 14.75%, dropping to INR 5,664.2 crore in FY 2024, compared to INR 6,643.9 crore in FY 2023.
- PharmEasy’s total expenditure decreased by 19.16%, falling to INR 7,254.8 crore in FY 2024 from INR 8,974 crore in FY 2023.
- Deeper penetration into Tier-2 & Tier 3 cities
- In FY 2024, PharmEasy generated INR 5,008 crore from the sale of medicines, while revenue from lab tests and other services amounted to INR 652 crore.
Read Also: Biggest Unlisted Companies in India
API Holdings Board of Directors
- Mr. Siddharth Shah, MD & CEO
- Dr. Dhaval Shah, Whole-time Director
- Mr. Hardik Dedhia, Whole-time Director
- Mr. Shyam Powar, Non-Executive Director
- Dr. Ranjan Pai, Non-Executive Director
- Mr. Dovaldas Buzinskas, Non-Executive Director
- Mr. Aditya Puri, Chairman, Non-Executive Director
- Mr. Deepak Vaidya, Independent, Non-Executive Director
- Mr. Ankur Thadani, Non-Executive Director
- Mr. Ashutosh Sharma, Non-Executive Director
- Ms. Vineeta Rai, Independent, Non-Executive Director
- Dr. Jaydeep Tank, Independent, Non-Executive Director
- Mr. Subramaniam Somasundaram, Independent, Non-Executive Director
PharmEasy Unlisted Share Details
Name | PharmEasy Unlisted Share Details |
Face Value | INR 1 per share |
ISIN Code | INE0DJ201029 |
Lot Size | 1,000 shares |
Demat Status | NSDL, CDSL |
API Holdings Unlisted Share Price | INR 8.40 per share |
Market Cap | INR 5,242 crore |
Total number of shares | 6,24,04,35,432 shares |
Website | www.pharmeasy.in |
PharmEasy Unlisted Share Details – Shareholding Pattern
Details of shareholders holding more than 5% of a class of equity shares in the company:
Shareholder Name | % to Holding | No. of shares |
Naspers Ventures B. V. | 13.03 | 81,33,16,570 |
MacRitchie Investments Pte. Ltd. | 11.74 | 73,25,16,290 |
TPG Growth V SF Markets Pte. Ltd | 7.20 | 44,94,92,340 |
Evermed Holdings Pte. Ltd. | 6.35 | 39,60,33,000 |
Prasid Uno Family Trust through its trustee Surbhi Singh | 4.39 | 27,39,83,731 |
Others | 57.29 | 3,57,50,93,501 |
PharmEasy Unlisted Share Details – Financial Metrics
Particulars | FY 2022 | FY 2023 | FY 2024 |
Revenue | 5,728.82 | 6,643.94 | 5,664.29 |
Expenses | 8,491.59 | 8,974.01 | 7,254.80 |
Net income | (3,992.50) | (5,211.73) | (2,533.51) |
Margin (%) | (69.69) | (78.44) | (44.73) |
ROCE (%) | – | (92.0) | (29.0) |
EBITDA (%) | (40.18) | (23.40) | (11.41) |
EPS | (7.28) | (8.51) | (4.07) |
Debt / Equity | – | 0.01 | 0.60 |
Read Also: Best IPOs That Doubled Investors’ Money
PharmEasy Annual Reports
PharmEasy Annual Report FY 2023 – 2024
PharmEasy Annual Report FY 2021 – 2022
PharmEasy Draft Red Herring Prospectus
PharmEasy Unlisted Share Peer Comparison
Company | 3-yr Sales CAGR (%) | ROCE (%) | Net Margin (%) | MCap (INR crore) |
PharmEasy (API Holdings) | 34.36 | (29.0) | (44.73) | 5,242 |
Apollo Hospitals (Apollo Pharmacy) | 21.8 | 15.1 | 4.91 | 1,02,451 |
PharmEasy Unlisted Share FAQs
Is it safe to purchase unlisted shares in India?
While there are risks associated with unlisted shares, purchases made from credible brokers and after conducting due diligence considerably lower these risks.
What is PharmEasy unlisted share price?
PharmEasy unlisted stock price in December 2024 is INR 8.40 per share. Shares are purchased in lots of 1,000 shares.
Who determines PharmEasy share price?
The unlisted share price is determined by various factors including recent transaction price, supply and demand, valuation in the latest funding round, profitability, and return ratios.
When is PharmEasy IPO planned?
PharmEasy’s parent API Holdings has also delayed internal plans for a potential IPO to 2025, the people privy to the goings-on at the company said on condition of anonymity.